



Company Announcement no. 14/2015

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, 3 June 2015

Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants

Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by 250,000 new shares with a nominal value of DKK 0.10 each corresponding to nominal DKK 25,000.00 as a consequence of the exercise of warrants by management and a former employee granted under the company's warrant program.

As a result of the employees investment in the company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 87,500.00. The subscription price for the new shares is DKK 0.35 per share of nominal DKK 0.10.

The new shares will be listed on NASDAQ OMX Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 166,334,073 divided into shares of DKK 0.10 each.

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.

For more information, please contact:

Veloxis Pharmaceuticals A/S

Bill Polvino
President & CEO
Phone: +1 732 321 3202
Email: wjp@veloxis.com

Johnny Stilou
EVP, Chief Financial Officer
Phone: +45 30 53 33 64
Email: jst@veloxis.com

Veloxis Pharmaceuticals A/S (VELO)

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.